Standard BioTools Holders Approve Reverse Split Range of 1-for-20 to 1-for-40

The charter amendment sets a ratio range, with the final ratio still to be agreed with Treeline Biosciences.

Young woman medical researcher looking through microscop slide in the life science (forensics, microbiology, biochemistry, ge
Photo: Cast Of Thousands/Shutterstock.com

Key terms

  • Ratio range approved: 1-for-20 to 1-for-40, final ratio to be agreed with Treeline
  • Stockholders approved on Nov. 19, 2026; 394,711,296 shares outstanding at Oct. 16 record date
  • Effective date and split-adjusted trading start not given in the filing
  • Proposed name change to Treeline Biosciences, Inc. included in the same amendment

Standard BioTools (Nasdaq: LAB) stockholders approved a reverse stock split at a virtual special meeting on Nov. 19, 2026, the company said in an 8-K filed the same day.

The approved charter amendment would effect a reverse split of the company's common stock at a ratio from 1-for-20 to 1-for-40, inclusive. The final ratio will be mutually agreed to by Standard BioTools and Treeline Biosciences, Inc. The same amendment would change the company's name to Treeline Biosciences, Inc.

Vote and share count

As of the Oct. 16, 2026 record date, 394,711,296 shares of common stock were outstanding and entitled to vote. Holders of about 71.38% of the voting power were present or represented by proxy. The charter amendment received 275,584,914 votes for, 6,123,396 against and 36,102 abstentions.

The filing does not give an effective date for the split or the date shares would begin trading split-adjusted. It does not say whether the ticker or CUSIP would change, how fractional shares would be handled, or what the share count would be after the split. It also does not give a reason for the split.

The same meeting approved the proposed merger with Treeline and the sale of the Mass Cytometry business to Element Biosystems, LLC. The company said the merger is expected to close in the fourth quarter of 2026. Before this filing, the company's market capitalization was about $240.8 million as of Nov. 1, and its last close was $0.61 on Nov. 19, 2026.

Sources

Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.

LAB page →

Filings, figures and price history are on the Standard Biotools page.